20cm Express｜The pharmaceutical sector experiences a major rebound, Guotai (159377) ChiNext Pharmaceutical ETF rises over 2%

Guojin Securities points out that the turnaround for innovative drug companies has arrived, with intensive clinical data catalysts throughout the year. Coupled with successful overseas clinical progress of BD pipelines, the company is optimistic about investment opportunities in the innovative drug sector. The domestic demand for medical devices is gradually recovering, and overseas expansion is entering an acceleration phase. Recently, policies and industry dynamics in this field have been dense, with innovation support and internationalization strategies advancing simultaneously. The National Medical Products Administration has approved an increasing number of innovative medical devices, with priority review focusing on core areas such as brain-computer interfaces and high-end imaging equipment; at the same time, the National Healthcare Security Administration has established new charging standards for surgical robots and related medical services, which may further accelerate the adoption of innovative products in hospitals.

The ChiNext Medical ETF, Guotai (159377), tracks the Chuangyi Medical Index (399275), which has a daily limit of 20% for gains and losses. This index selects securities of listed companies engaged in biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services within the innovative healthcare sector from the Shanghai and Shenzhen markets, reflecting the overall performance of innovative biotech and pharmaceutical listed companies. The index emphasizes R&D investment and technological leadership of constituent companies, focusing on high-growth potential healthcare sectors.

Risk Reminder: Mentioning individual stocks is only for industry event analysis and does not constitute any stock recommendation or investment advice. Short-term index fluctuations are for reference only and do not predict future performance, nor do they constitute a promise or guarantee of fund performance. Views may change with market conditions and do not constitute investment advice or commitments. Different funds have varying risk and return characteristics; investors should carefully read the fund legal documents, fully understand product features, risk levels, and income distribution principles, and choose products that match their risk tolerance. Invest cautiously.

Daily Economic News